Farther Finance Advisors LLC Has $812,000 Holdings in Sanofi $SNY

Farther Finance Advisors LLC increased its position in Sanofi (NASDAQ:SNY) by 201.1% during the third quarter, Holdings Channel.com reports. The firm owned 17,197 shares of the company’s stock after buying an additional 11,486 shares during the quarter. Farther Finance Advisors LLC’s holdings in Sanofi were worth $812,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SNY. Ameritas Advisory Services LLC acquired a new position in shares of Sanofi during the second quarter valued at about $28,000. Banque Transatlantique SA bought a new position in Sanofi in the 1st quarter valued at about $33,000. Concord Wealth Partners boosted its stake in Sanofi by 510.3% during the 2nd quarter. Concord Wealth Partners now owns 885 shares of the company’s stock valued at $43,000 after purchasing an additional 740 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Sanofi by 233.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after purchasing an additional 700 shares in the last quarter. Finally, Traub Capital Management LLC bought a new stake in Sanofi during the 2nd quarter worth approximately $51,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Stock Down 0.2%

Shares of NASDAQ:SNY opened at $48.35 on Tuesday. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a market capitalization of $118.70 billion, a PE ratio of 11.32, a price-to-earnings-growth ratio of 1.32 and a beta of 0.44. The business has a fifty day moving average price of $49.62 and a two-hundred day moving average price of $48.88. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.30.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. The company had revenue of $15.46 billion for the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business’s revenue for the quarter was down 7.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.25 EPS. Analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HSBC restated a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Finally, Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.